Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study

NCT03727763 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT03727763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03727763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 8, 2018
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer